This is Mixed Connective Tissue Disease (MCTD) with Inflammatory Myositis, Not Multiple Sclerosis
Based on the markedly elevated anti-U1 ribonucleoprotein antibodies, rising creatine kinase, and inflammatory myositis presentation, this patient has MCTD with myositis rather than multiple sclerosis. The periventricular white matter hyperintensities are likely related to the underlying connective tissue disease vasculopathy, not demyelinating disease.
Key Diagnostic Reasoning
Why This is MCTD, Not MS:
The anti-U1 RNP antibodies are pathognomonic for MCTD and are necessary for diagnosis 1. The markedly elevated levels in this patient, combined with rising CK, definitively point toward MCTD with inflammatory myositis rather than MS.
The rising creatine kinase is the critical distinguishing feature. MS does not cause elevated CK. This biochemical marker indicates active muscle inflammation characteristic of MCTD-associated myositis 2. Recent data shows MCTD myositis patients commonly present with proximal muscle weakness and elevated muscle enzymes, with some requiring intensive immunosuppressive therapy 2.
The speckled ANA pattern with anti-U1 RNP positivity creates a diagnostic signature incompatible with MS. While MS patients may occasionally have positive ANA, they do not have anti-U1 RNP antibodies 1.
The White Matter Hyperintensities Explained:
The periventricular white matter hyperintensities in this case are not the demyelinating lesions of MS. Here's why:
MS lesions have specific morphologic requirements 3: They must be ovoid, perpendicular to ventricles (Dawson's fingers), demonstrate the central vein sign (CVS), involve juxtacortical U-fibers, and affect characteristic locations (corpus callosum, brainstem, cerebellum)
MCTD causes white matter changes through vasculopathy, not demyelination. The underlying autoimmune vasculitis in connective tissue diseases produces different imaging patterns 4
The ESR/CRP dissociation (elevated ESR with low-normal CRP) is characteristic of connective tissue diseases, not MS, which typically shows normal inflammatory markers unless there's concurrent infection
Clinical Pitfalls to Avoid:
Do not be misled by periventricular hyperintensities alone. These are nonspecific findings that occur in multiple conditions including MCTD vasculopathy, small vessel disease, and aging 5. The 2024 MAGNIMS-CMSC-NAIMS consensus emphasizes that deep white matter lesions have low specificity for MS and require additional features (CVS, paramagnetic rim, specific anatomical distribution) for diagnostic confidence 3.
The absence of typical MS features is telling:
- No mention of optic neuritis
- No spinal cord involvement
- No dissemination in time with new lesions
- No gadolinium enhancement pattern typical of MS
- No juxtacortical or cortical lesions with U-fiber involvement
MCTD Myositis Phenotype Considerations:
This patient may have a severe systemic sclerosis phenotype within their MCTD. Recent evidence shows that certain MCTD patients with high-titer autoantibodies develop more aggressive disease with myositis, myocarditis, and gastrointestinal involvement 4. The G6PD deficiency is a separate consideration for medication selection but doesn't alter the primary diagnosis.
MCTD myositis often shows heterogeneous pathology 2. Some patients demonstrate dermatomyositis-like features, while others show nonspecific inflammatory infiltrates predominantly in perivascular regions. The therapeutic response to immunosuppression is typically favorable 2.
Management Implications:
Cancer screening is mandatory. Given the inflammatory myositis component, this patient requires comprehensive malignancy screening per IMACS guidelines 6. MCTD patients with myositis features should undergo enhanced cancer screening including CT imaging and tumor markers, particularly within the first 3 years of diagnosis.
Treatment should target the autoimmune myositis with corticosteroids as first-line therapy, potentially requiring additional agents like IVIG, mycophenolate mofetil, or rituximab for refractory cases 7. The G6PD deficiency necessitates avoiding oxidative stress-inducing medications.